P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)

Detalles Bibliográficos
Autores principales: Silva-Pinto, A. C., Colombatti, R., Pasanisi, A., Arcioni, F., DeBonnett, L., Soliman, W., Sarkar, R., Cançado, R. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429287/
http://dx.doi.org/10.1097/01.HS9.0000848820.30412.22
_version_ 1784779393399259136
author Silva-Pinto, A. C.
Colombatti, R.
Pasanisi, A.
Arcioni, F.
DeBonnett, L.
Soliman, W.
Sarkar, R.
Cançado, R. D.
author_facet Silva-Pinto, A. C.
Colombatti, R.
Pasanisi, A.
Arcioni, F.
DeBonnett, L.
Soliman, W.
Sarkar, R.
Cançado, R. D.
author_sort Silva-Pinto, A. C.
collection PubMed
description
format Online
Article
Text
id pubmed-9429287
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94292872022-08-31 P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP) Silva-Pinto, A. C. Colombatti, R. Pasanisi, A. Arcioni, F. DeBonnett, L. Soliman, W. Sarkar, R. Cançado, R. D. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429287/ http://dx.doi.org/10.1097/01.HS9.0000848820.30412.22 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Silva-Pinto, A. C.
Colombatti, R.
Pasanisi, A.
Arcioni, F.
DeBonnett, L.
Soliman, W.
Sarkar, R.
Cançado, R. D.
P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_full P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_fullStr P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_full_unstemmed P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_short P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
title_sort p1491: real-world incidence of vaso-occlusive crises in patients with sickle cell disease (scd) and a high baseline disease burden treated with crizanlizumab: results from a managed access program (map)
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429287/
http://dx.doi.org/10.1097/01.HS9.0000848820.30412.22
work_keys_str_mv AT silvapintoac p1491realworldincidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabresultsfromamanagedaccessprogrammap
AT colombattir p1491realworldincidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabresultsfromamanagedaccessprogrammap
AT pasanisia p1491realworldincidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabresultsfromamanagedaccessprogrammap
AT arcionif p1491realworldincidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabresultsfromamanagedaccessprogrammap
AT debonnettl p1491realworldincidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabresultsfromamanagedaccessprogrammap
AT solimanw p1491realworldincidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabresultsfromamanagedaccessprogrammap
AT sarkarr p1491realworldincidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabresultsfromamanagedaccessprogrammap
AT cancadord p1491realworldincidenceofvasoocclusivecrisesinpatientswithsicklecelldiseasescdandahighbaselinediseaseburdentreatedwithcrizanlizumabresultsfromamanagedaccessprogrammap

Ejemplares similares